Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients

NCT05399251 | Completed

• 1 other identifier: ERC # 2020-3295-14097
• Study Type: observational
• Target: 1,553
• Locations: 0 countries
• Sites: N/A

Brief Summary

This cross-sectional study was conducted, including those subjects tested for 1,25(OH)2D during Jan 2015-Dec 2021. Estimated glomerular filtration rate (eGFR) was calculated and subjects were classified into chronic kidney disease (CKD) stages. Associations between biochemical marker, calcium, phosphorus, magnesium, alkaline phosphatase, 1,25(OH)2D and CKD stages was determined.

Conditions

Chronic Kidney Disease-Mineral and Bone Disorder

Keywords

renal dysfunction; bone metabolism marker; 1,25(OH)2 vitamin D

Outcome Measures

Primary Outcomes (2)

• concentration of serum 1,25 dihydroxy vitamin D in U/L in five stages of chronic kidney disease

  In CKD, 1-alfa-hydroxylase activity in the kidneys is reduced, leading to decreases in the level of the activated form of vitamin D (1,25- dihydroxy vitamin D), resulting in secondary hyperparathyroidism and bone disease. This study aimed to determine the concentration of 1,25 dihydroxy vitamin D in different stages of CKD.

  7 year

• concentration of serum calcium in mg/dl in five stages of chronic kidney disease

  in renal tubules, 1,25- dihydroxy vitamin D increase reabsorption of calcium from renal filtrate and thus stabilize blood calcium levels. in CKD, with deterioration of kidney function, stage V, the levels of calcium drops resulting in hypocalcemia.

  7 years

Eligibility Criteria

• Age: 20 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Laboratory data of patients tested for 1,25(OH)2D from January 2015 to December 2021 was retrieved from laboratory integrated systems (ILMS), and only the initial results for 1,25(OH)2D were included.

You may qualify if:

• Data of serum 1,25(OH)2D available

You may not qualify if:

• Serum1,25(OH)2D is not available

Sponsors & Collaborators

• Aga Khan University Hospital, Pakistan: lead

MeSH Terms

Conditions

Chronic Kidney Disease-Mineral and Bone Disorder; Renal Insufficiency

Condition Hierarchy (Ancestors)

Rickets; Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Calcium Metabolism Disorders; Vitamin D Deficiency; Avitaminosis; Deficiency Diseases; Malnutrition; Nutrition Disorders; Hyperparathyroidism, Secondary; Hyperparathyroidism; Parathyroid Diseases; Endocrine System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PRINCIPAL INVESTIGATOR

Study Record Dates

• First Submitted: February 14, 2022
• First Posted: June 1, 2022
• Study Start: January 1, 2015
• Primary Completion: December 30, 2021
• Study Completion: December 30, 2021
• Last Updated: June 1, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share